Investors

Investor Relations

Akebia Therapeutics

Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.

We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.

OUR MEDICINE

RESEARCH & DEVELOPMENT

Press Releases

October 15, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

October 10, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

October 7, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

VIEW ALL PRESS RELEASES

Events & Presentations

September 9, 2024 at 10:30 AM EDT

H.C. Wainwright 26th Annual Global Investment Conference

September 6, 2024 at 9:30 AM EDT

Wells Fargo 2024 Healthcare Conference

August 14, 2024 at 8:30 AM EDT

Canaccord Genuity 44th Annual Growth Conference

VIEW ALL EVENTS

Data Presentations

Presented at ASN Kidney Week 2021

Comprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials

Presented at ASN Kidney Week 2021

Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis

Presented at ASN Kidney Week 2021

Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia Due to CKD

VIEW ALL DATA PRESENTATIONS

Volume:

Today’s Open:

Previous Close:

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax